| abstract |
The pharmaceutical composition comprises a sulfonamide compound in combination with a substance having EGF inhibitory activity, wherein the sulfonamide compound is: N- (3-chloro-1H-indol-7-yl) -4-sulfamoylbenzenesulfonamide, N- (3-cyano- 4-methyl-1H-indol-7-yl) -3-cyanobenzenesulfonamide, or a pharmacologically acceptable salt or solvate thereof, wherein the substance having EGF inhibitory activity is gefitinib, erlotinib or cetuximab. The patent contains 9 more patent claims. |